3 Results for "

TEAD-YAP interactions

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "TEAD-YAP interactions" in MCE Product Catalog:

Cat. No.: HY-183728
Target:  

YAP

Research Areas:  

Cancer

LC-TEAD01 is a potent covalent transcription enhancer-associated domain (TEAD) inhibitor with an IC50 of 116 nM and a Ki of 0.132 μM. LC-TEAD01 disrupts the TEAD-YAP interaction and inhibits TEAD-dependent transcriptional activity. LC-TEAD01 suppresses the proliferation of NF2-deficient cancer cells. LC-TEAD01 inhibits tumor growth in NF2-deficient xenograft models. LC-TEAD01 can be used in studies related to NF2-deficient malignant pleural mesothelioma .
loading...
    loading...
Cat. No.: HY-187181
CAS No.: 2933893-78-6
Target:  

YAP Hippo (MST)

Research Areas:  

Cancer

GNE-2181 is an orally active, blood-brain barrier-penetrant pan-TEAD transcription factor inhibitor, with IC50 values of 13, 26, 61 and 17 nM against TEAD1, TEAD2, TEAD3 and TEAD4, respectively. GNE-8021 allosterically disrupts the TEAD-YAP/TAZ interaction and inhibits TEAD-mediated oncogenic transcriptional programs via the Hippo signaling pathway. GNE-8021 suppresses YAP-driven tumor cell growth. GNE-2181 inhibits the growth of intracranial tumor models in vivo. GNE-2181 can be used for research on brain metastasis of lung cancer .
loading...
    loading...
Cat. No.: HY-187180
CAS No.: 2933893-27-5
Research Areas:  

Cancer

GNE-8025 is an orally active pan-TEAD transcription factor inhibitor, with IC50 values of 45, 38, 1035 and 24 nM against TEAD1, TEAD2, TEAD3 and TEAD4, respectively. GNE-8025 allosterically disrupts the TEAD-YAP/TAZ interaction and inhibits TEAD-mediated oncogenic transcriptional programs via the Hippo signaling pathway. GNE-8025 suppresses YAP-driven tumor cell growth. GNE-8025 enhances the activity of MAPK and KRAS G12C inhibitors. GNE-8025 can be used for the research of pleural mesothelioma and KRAS G12C-mutant cancers .
loading...
    loading...